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INTRODUCTION
The CSCs has been identified as a subpopulation of stem-like cells within tumors exhibiting characteristics of both stem cells and cancer 
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ABSTRACT
Background: Cancer stem cells (CSCs) as a class of malignant cancer cells play an important role in tumor progression. Previous 
studies by our group have demonstrated the establishment of the model of CSCs converting mouse iPS cells (miPSCs) into 
CSCs by treating the miPSCs with a conditioned medium (CM) of Lewis Lung Carcinoma (LLC) cells with or without the non-
mutagenic chemical compounds. CSCs converted from miPSCs developed highly malignant adenocarcinoma when subcutaneously 
transplanted into the nude mice. 
Methods: The miPSCs were treated with each compound for 1 week in the presence of a CM of LLC cells. We evaluated the gene 
expression in the resultant CSCs comparing that in miPSCs by microarray analysis. And the expression of chemokine (C-C motif) 
ligand 20 (CCL20) and C-C chemokine receptor type 6 (CCR6) in converted cells were evaluated by rt-qPCR. The CCR6 expression 
in converted cells and primary cells were determined by flow cytometry.
Results: As the result, the expression of CCL20 was found upregulated in the presence of CM supplemented with PD0325901. Then 
we assessed the expression of CCR6, which was considered to be stimulated by CCL20. Then the expression of CCR6 was also found 
up-regulated. Interestingly, IL17A expression was also observed only in the CSCs from the primary tumor implying the effect of 
tumor microenvironment. Moreover, significantly high level of CCR6 was showed in flow cytometric analysis.
Conclusion: These results suggest that a model of CSCs with CCL20-CCR6 autocrine loop was obtained as the result of the conversion 
of iPSCs. This CSC should be a good model to study targeting CCR6 as a G protein-coupled receptor (GPCR).
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cells. CSCs are characterized by the abilities of self-renewal, differentiation in vitro and tumorigenesis in vivo [1]. CSCs are nowadays 
generally accepted to represent a unique 
population of cancer tissues that are tumorigenic, 
and resistant to most chemotherapeutic agents 
and radiation therapy, supporting cancer 
progression and recurrence.The molecular and cellular mechanisms of cancer 
progression are now significantly being studied 
due to the finding of CSCs. Chronic inflammation is considered one of the reasons essential for 
cancer initiation and progression providing a tumor microenvironment. Chemokines are 
known to play a prominent role in inflammation 
and spreading of cancer. Therefore, chemokines 
and their cognate receptors should be the 
important factors involved in wound healing and 
angiogenesis. The ligands and their receptors are 
generally expressed in various cells in response 
to inflammation to recover homeostasis from imbalanced situation [2].On the other hand, the chemokine CCL20 is 
considered a sole known ligand specific to CCR6, one of the GPCRs. Their interaction has been 
confirmed in B and T cells as well as dendritic cells (DCs) [3-5]. Recently, CCR6 has been 
shown in promoting non-small-cell-lung- cancer (NSCLC) carcinogenesis [6]. The chemokine/
chemokine receptor pair CCL20/CCR6 is a key 
player in lung immunity [7]. The interaction of CCL20 and CCR6 is thought to trigger the 
inflammation, which leads to cell chemotaxis [8,9]. Furthermore, recent research targeting the biological function of CCR6 indicates a 
significant role for this chemokine receptor in 
the development of NSCLC [10].
Previously, our group has demonstrated the 
development of CSCs from miPSCs treating with the CM derived various cancer cell lines [11-
13]. The conditioned medium was supposed to be enriched with various factors related with the tumor microenvironment including 
inflammatory cytokines, chemokines and growth factors. In this study, we demonstrated the 
expression of CCL20 and CCR6 be upregulated 
in the presence of CM supplemented with 
PD0325901. And significantly high level of CCR6 
was detected in flow cytometric analysis. The 
CCL20/CCR6 axis was involved in the progression of the conversion of CSCs. We suggested that a 
model of CSCs with CCL20-CCR6 autocrine loop was obtained as the result of the conversion of iPSCs. This CSC model should be a good model to study targeting CCR6 as a GPCR. 
MATERIALS AND METHODS
Materials
Mouse induced pluripotent stem cells (miPSCs, iPS-MEF-Ng-20D-17; Lot No.012) were 
provided from RIKEN Cell Bank, Japan. DMEM, 
2-mercaptoethanol, collagenase, gelatin, Hematoxylin and Eosin Y were from Sigma, 
NY. KnockOutTM Serum Replacement (KSR) and Non-Essential Amino acids (NEAA) were 
from Gibco, NY. L-Glutamine, 2.5% Trypsin and CaCl2 were from Nacalai Tesque, Japan. 100 U/
ml penicillin/streptomycin (P/S) cocktail were 
from Wako, Japan. Leukemia inhibitory factor 
(LIF) was from Millipore, MA. Mitomycin C 
treated mouse embryonic fibroblasts (MEF) 
were provided from Reprocell, Japan. Mouse Lewis lung carcinoma (LLC) cells were obtained from ATCC, VA, USA. PD0325901 (391210-10-9) 
and CHIR99021 (252917-06-9) were purchased 
from Selleck Chemicals, Japan. Dasatinib 
(302962-49-8) was purchased from AdooQ 
BioScience, USA.
Anti-mouse CCR6 goat polyclonal antibody 
(NB100-713) was purchased from Novus 
Biologicals USA. Donkey polyclonal anti-Goat lgG-H&L (Alexa Fluor®647) antibody (ab150135) 
was purchased from Abcam, UK. Horseradish 
peroxidase (HRP)-conjugated anti-goat IgG donkey 
polyclonal antibody (sc-2020) was purchased from cell santa cruz biotechnology, Inc. Anti-
mouse β-actin rabbit polyclonal antibody (4970), 
HRP-conjugated anti-rabbit IgG goat polyclonal 
antibody (7074) were purchased from Cell Signaling Technology, MA, USA.
Cell culture
miPSCs were maintained in DMEM supplemented 
with 15% FBS, 0.1mm NEAA, 2 mm L-Glutamine, 
50 U/ml P/S, 0.1 mm 2-mercaptoethanol and 1000 U/ml of LIF on feeder layers of mitomycin C treated MEF. In the case of feeder-less, the miPSCs were cultured on gelatin coated dishes. LLC cells were maintained in DMEM containing 
10% FBS supplemented with 100 U/ml P/S. 
To prepare the CM from LLC cells, the medium 
was collected as previously described. The mixture of CM and miPS medium (1:1) was 
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supplemented with each signal inhibitor. The miPSCs were cultured in the mixed medium without LIF and MEF feeder cells. One half of the 
medium was replaced with fresh mixed medium 
every day up to day 6. On day 7, the expression 
of GFP and cell morphology was observed and 
photographed using an inverted fluorescent 
microscope (Olympus IX81, Japan).
RNA extraction, cDNA synthesis and reverse 
transcription quantitative PCR analysisTotal RNA was extracted from cells using 
the RNA easy Mini kit (QUIAGEN, Germany) and treated with DNase according to the 
manufacturer's instructions and 1 μg of RNA was 
reverse transcribed using the Superscript First-
Strand kit (Invitrogen, CA). Reverse transcription 
quantitative PCR (rt-qPCR) was performed with 
SYBR green I Master Mix (Roche, Switzerland) using LightCycler® 480 Instrument (Roche, Switzerland) according to manufacturer’s instructions (Table 1).
Microarray analysis of gene expression
Total RNA was extracted with QIAGEN RNeasy kit and isolated RNA was treated with DNase as described avove. Then the RNA was used as 
the template of cDNA, which was subjected to 
microarray analysis employing SurePrint G3 
Mouse Gene Expression (Agilent, CA, USA).
Self-organizing map analysis
The spectrum data obtained from microarray 
was analyzed by SOM (SOM Japan Inc., Japan). 
The values of read from the hybridized spots were 
compared and the difference between the miPSCs treated with PD0325901 and the average values of miPSCs treated with or without ATRA in the 
presence of CM was calculated. SOM was used to 
find an ideally expressed gene, which was named as 
an ideal probe (IP), then the genes were clustered by SOM with the distance of each gene from the IP 
gene supposed to be expressed in miPSCs treated with PD0325901 but not in miPSCs treated with or 
without ATRA in the presence of CM.
Flow cytometryThe miPSCs that survived following the 1-week treatment were transferred to a 60-mm dish 
were harvested with a rubber scraper. The cells 
were then dissociated by passing through a mesh and incubated with anti-mouse CCR6 antibody (1:50) in 100µL for 30 min at 4℃ Cells were 
washed with ice-cold PBS and incubated with the secondary antibody (1:500) in 100µL for 30 min at 4℃ followed by wash with ice-cold PBS. 
The resultant cells were re-suspended in 100µL 
of ice-cold PBS and analyzed by a flow cytometer 
(BD AccuriTM C6 plus, Becton & Dickinson, NJ). 
Data from each experiment was analyzed by FlowJo software (FlowJo, LLC, Ashland, OR, USA).
Statistical analysis
The fluorescence data read by the microplate reader were analyzed using the two-tailed 
student’s t-test and presented as the mean ± 
standard deviation (SD) from independent 
experiments repeated at least three times. The 
statistical significance in mean values between 
two groups was determined by 2-tailed student’s 
t-test and expressed as the mean values. In the 
data acquired from the rt-qPCR analysis, the 
statistical significance between the mean values 
of more than two groups was determined using one-way analysis of variance (ANOVA) and 
Dunnett's multiple comparisons test. P<0.05 was 
considered statistically significant.
RESULTS AND DISCUSSION
The effect of chemical compounds during the 
conversion of miPSCs into CSCsPreviously, we found the miPSCs converted into CSCs, exhibiting self-renewal, differentiation 
potential and tumorigenesis, in the presence of a CM of cancer derived cell lines in 4 weeks 
[11-13]. We employed miPSCs expressing a 
gene encoding green fluorescent protein (GFP) 
under the control of the Nanog promoter [14] to distinguish the undifferentiated/differentiated 
condition of the cells. In miPSCs, GFP fluorescence 
is kept on during the undifferentiated state, 
while GFP fluorescence is turned off when the miPSCs differentiated in the absence of leukemia 
inhibitory factor (LIF). Applying this procedure, in this study we evaluated the risk of non-
Names Accession Forward Primer Sequence 5’- 3’ Reverse Primer Sequence 5’- 3’
CCL20 NM_016960.2 CGACTGTTGCCTCTCGTACA GCTTCATCGGCCATCTGTCT
CCR6 NM_001190334.1 AGCTCAGCATTTTCTGGGCTTCA GTGATGGGCTCTGAGACAGAC
IL17A NM_010552 GGGTCTTCATTGCGGTGGAGAG ATCCCTCAAAGCTCAGCGTGTC
IL17A Receptor NM_008359.2 ACAGTTCCCAAGCCAGTTGC TCAGCACGATGACAGATCCC
Table 1: Primers used.
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mutagenic chemical compounds to accelerate the conversion, which was considered as CSSC 
induction. Most of the compounds assessed 
were the inhibitors of cytoplasmic signaling 
pathways. As the results, the expression of 
GFP fluorescence were obviously maintained after 1 week when miPSCs were cultured 
with PD0325901 in the presence of CM from LLC cells (Figure 1). In contrast, All-Trans 
Retinoic Acid (ATRA) significantly accelerated 
diminishing GFP fluorescence indicating the cells differentiated. In our recent study, we 
have demonstrated that three compounds, PD0325901, CHIR99021 and Dasatinib, out of 110 could accelerate the conversion of miPSCs 
into CSCs, and the expression of GFP fluorescence were maintained. PD0325901 is known as an inhibitor of MEK, and MEK is a main downstream of tyrosine kinases from Ras/Raf/MAP kinase cascade. Since Dasatinib is known as the tyrosine kinase inhibitor of src, bcl and c-kit, PD0325901 
and Dasatinib appeared to have similar role in converting miPSCs into CSCs. When PD0325901 combined with CHIR99021 together the self-
renewal potential of mouse ESCs was maintained 
while CHIR99021 was an inhibitor of GSK-3β [15]. In this context, the functions of three inhibitors might closely be related one another to enhance 
the expression of GFP fluorescence and maintain the stemness resulting in the conversion from miPSCs into CSCs.
Gene expression difference during the conversion 
into CSCs treated with MEK inhibitor
We analyzed the difference of gene expression between the cells treated with PD0325901and ATRA by microarray followed by gene clustering 
analysis with sphere self-organizing map (sSOM) 
[16-18]. First of all, miPSCs and miPSCs treated 
with the CM was compared to reveal the genes which is related to CSC conversion. There were 
507 up-regulated and 447 down-regulated genes (Figure2A). PD0325901 could have effects on 
them during the CSCs conversion. The expression 
of these 964 genes were further compared between the miPSCs treated with CM and PD0325901 and those treated with CM and 
ATRA. Then we found 69 genes upregulated and 320 gens downregulated by PD0325901 
(Figure 2B). We supposed an IP, which was 
not expressed in miPSCs treated with CM or 
with CM and ATRA, but highly expressed in miPSCs treated with CM and PD0325901. 
The relationships of each gene and IP were 
analyzed by sSOM and depicted on the sphere (Figure 2C and 2D). The distances reflected 
on the sphere between each gene and the IP was sorted from the shortest to the longest 
and the a part of the shortest genes are shown in Table 2. The more effect should be on the gene by PD0325901 if the distance from the 
gene is closer to IP. From this point of view, we thought CCL20 could be the candidate to 
be analyzed for the relationship with CSCs and PD0325901 because CCL20 is known as a chemokine stimulating CCR6, which was a 
GPCR activating PI3K signaling pathway.
Expression of CCL20 and CCR6 in converted cells and 
primary cultured cells was upregulated
We further analyzed the expression of CCR6 and CCL20 in miPSCs treated with PD0325901, 
CHIR99021 and Dasatinib, using rt-qPCR. The 
expression level of CCR6 and CCL20 were found 
to be up-regulated during the 7 days of treatment 
(Figure 3A). Our previous work demonstrated 
Figure 1: Representative images of the conversion from miPSCs into CSCs. Cells were cultured with media containing CM and positive 
(PD0325901) / negative (All-Trans Retinoic Acid) chemical compound, colonies were observed for the GFP expression after 1 week of 
treatment.
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that the miPSCs treated with the three compounds exhibited tumorigenicity when subcutaneously 
transplanted into Balb/c nude mice. Meanwhile, 
we evaluated the expression of CCR6 and CCL20 
in the primary cells derived from the tumors formed in nude mice (Figure 3B). As the result, 
the significantly highly expression of CCR6 as 
well as CCL20 was found in the primary cells.
Expression of IL17A in primary cultured cells was 
detected
Recent studies have reported that IL17A, of 
which expression was driven by TGF-β and IL-6, 
Figure 2: Comparisons of gene expression among miPSC and 1 week converted cells. Microarray was performed on original miPSC and 
converted cells and their expression value were compared in binary logarithm among. (A) miPSC and miPSC+CM, and (B) miPSC+CM+All 
trans retinoic acid (ATRA) and miPSC+CM+PD0325901. (C and D) The relationships of each gene and IP were depicted on the sphere (Glyph 
Analysis Setting > Dent rate = 1).Table 2: Distance from ideal probe and heat map for their expression levels.
From IP Agilent ID a  b  c Systematic Name David ID Name 
0 A_51_P323770
 
NM_183271 68221 WAP four-disulfide core domain 15A (Wfdc15a)
0.404 A_52_P455370 NM_175628 232345 alpha-2-macroglobulin (A2m)
0.406 A_66_P101506 AK077242   
0.453 A_55_P2728797 AK018940 68208 RIKEN cDNA 1700039O17 gene (1700039O17Rik)
0.453 A_55_P2168383 NM_028901 74376 Myosin XVlllb (Myo18b)
0.46 A_52_P467488 NM_029529 76157 Solute carrier family 35, member D3 (Slc35d3)
0.7 A_55_P2731446 XM_011245278 101055806 Predicted gene 10378 (Gm10378)
1.281 A_51_P408595 NM_016960 20297 Chemokine (C-C motif) ligand 20 (CCL20)
1.551 A_51_P315391 NM_138628 378431 Taxilin beta (Txlnb)
1.6 A_51_P471659 NM_145684 11685 Arachidonate lipoxygenase, epidermal (Alox12e)
1.656 A_55_P2900459 XR_868020   
1.675 A_55_P1955871 NM_175290 97895 NLR family, pyrin domain containing 4F (Nlrp4f)
1.675 A_51_P208145 NM_021882 20431 Premelanosome protein (Pmel)
1.767 A_55_P2153021 NM_011652 22138 Titin (Ttn)
1.767 A_52_P306007 NM_024271 76413 RIKEN cDNA 1700016D06 gene (1700016D06Rik)
1.858 A_51_P291227 NM_001005508 226652 Rho GTPase activating protein 30 (Arhgap30)
1.858 A_55_P2031999 NM_145448 217830 RIKEN cDNA 9030617O03 gene (9030617O03Rik)
*The maximum distance from IP is 4.222, and genes whose distance is less than 2 is shown in this list.  
(A: miPSC+CM, B: miPSC+CM+PD0325901, C: miPSC+CM+ARTA)
Table 2: Distance from ideal probe and heat map for their expression levels.
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Figure 3A: Expression of CCL20 and CCR6 in converted cells, Il17A, CCL20 and CCR6 in primary cultured cells. RT-qPCR analysis of CCR6 and 
CCL20 in the converted cells.
Figure 3B: Expression of CCL20 and CCR6 in converted cells, Il17A, CCL20 and CCR6 in primary cultured cells. RT-qPCR analysis of CCL20, CCR6 
and Il17A in the primary cells from tumors. The data were analyzed using ordinary one-way ANOVA multiple comparisons and presented as 
the mean ± standard deviation ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.
induced CCL20 expression via the transcription 
factor STAT3 resulting in promoting tumor 
progression, and metastasis by upregulating the 
expression of the genes were involved in anti-
apoptotic, growth factors and angiogenesis [19-21]. However, these events were considered to 
be iunduced T lymphocytes. It may be explained 
by the presence of tumor associated macrophage 
(TAM) expressing the CCL20 surrounding the 
CSCs. We could not find the expression of IL17A in CSCs just after conversion of miPSCs while 
the slight upregulation of IL17A expression was 
detected in the primary cells from the tumor 
(Figure 3B). In the tumor microenvironment 
(TME), continuous exposure to CCL20 may 
have induced the expression of CCL20 in CSCs establishing autocrine stimulation of CCR on the 
CSCs transducing the signal to PI3K pathway. The 
expression of IL17A in the primary cells possibly 
implies the stimulation of the TAM to enrich 
the CCL20 in the TME although the significant 
expression of IL17AR was not observed in both CSCs just after conversion and those from 
primary tumor.
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Figure 4: CCR6 expression in converted cells and primary cells by flow cytometry. (A) Flow cytometry analysis shows CCR6 population in 
the converted cells after treated with chemical compounds. (Left: relative expression of cells without treatment by CCR6 (control). (Right: 
relative expression of cells with treatment by CCR6) (B) Flow cytometry analysis shows CCR6 population in the primary cells. (Left: relative 
expression of cells without treatment by CCR6 (control).
The inhibitors enhanced the expression of CCR6
Upregulation of the CCR6 expression was essentially related with organ orientation and 
significantly related with the metastasis of lung 
cancer [22-24]. We further evaluated the expression 
of CCR6 by flow cytometry and western blot. In 
flow cytometry, the CCR6-postive population in 
the presence of CM was found 41.1%, 21.7% and 31.6% in the cells when treated with PD0325901, 
CHIR99021 and Dasatinib, respectively while 
27.4% in miPSCs. CCR6-postive population was 3.9% of miPSCs in the absence of the CM (Figure 
4A). In the primary cells from the tumors, CCR6-
postive population was significantly increased to 53.4%, 83.1% and 61.5% in the cells derived from 
primary tumors, primary-miPSCs+CM+PD0325901, 
primary-miPSCs+CM+CHIR99021 and primary-
miPSCs+CM+Dasatinib, respectively (Figure 4B). 
CCR6-postive population was 10.6% of primary-miPSCs cells. 
CONCLUSIONIn conclusion, our study demonstrated the 
expression of CCL20 and CCR6 be upregulated 
in the presence of CM supplemented with PD0325901. And significantly high level of CCR6 was detected in flow cytometric analysis. The CCL20/CCR6 axis was involved in the 
progression of the conversion of CSCs. We suggested that a model of CSCs with CCL20-
CCR6 autocrine loop was obtained as the result of the conversion of iPSCs. This CSC model should be a good model to study targeting CCR6 as a GPCR.
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